

Paul W Hruz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3103238/publications.pdf>

Version: 2024-02-01

57
papers

3,098
citations

172207

29
h-index

161609

54
g-index

59
all docs

59
docs citations

59
times ranked

3948
citing authors

#	ARTICLE	IF	CITATIONS
1	Letter to the Editor from William J. Malone et al: "Proper Care of Transgender and Gender-diverse Persons in the Setting of Proposed Discrimination: A Policy Perspective" Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3287-e3288.	1.8	4
2	Deficiencies in Scientific Evidence for Medical Management of Gender Dysphoria. Linacre quarterly, The, 2020, 87, 34-42.	0.1	14
3	Lactotrehalose, an Analog of Trehalose, Increases Energy Metabolism Without Promoting Clostridioides difficile Infection in Mice. Gastroenterology, 2020, 158, 1402-1416.e2.	0.6	23
4	Letter to the Editor: "Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline" Journal of Clinical Endocrinology and Metabolism, 2019, 104, 686-687.	1.8	12
5	Identification of druggable small molecule antagonists of the Plasmodium falciparum hexose transporter PfHT and assessment of ligand access to the glucose permeation pathway via FLAG-mediated protein engineering. PLoS ONE, 2019, 14, e0216457.	1.1	19
6	Experimental Approaches to Alleviating Gender Dysphoria in Children. The National Catholic Bioethics Quarterly, 2019, 19, 89-104.	0.1	1
7	Metabolic and Cardiac Adaptation to Chronic Pharmacologic Blockade of Facilitative Glucose Transport in Murine Dilated Cardiomyopathy and Myocardial Ischemia. Scientific Reports, 2018, 8, 6475.	1.6	8
8	Evaluating the Efficacy of GLUT Inhibitors Using a Seahorse Extracellular Flux Analyzer. Methods in Molecular Biology, 2018, 1713, 69-75.	0.4	6
9	Contribution of systemic inflammation to permanence of K ⁺ ATP ⁻ -induced neonatal diabetes in mice. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E1121-E1132.	1.8	1
10	TFEB-dependent induction of thermogenesis by the hepatocyte SLC2A inhibitor trehalose. Autophagy, 2018, 14, 1959-1975.	4.3	23
11	MEPicides: potent antimalarial prodrugs targeting isoprenoid biosynthesis. Scientific Reports, 2017, 7, 8400.	1.6	26
12	Development of GLUT4-selective antagonists for multiple myeloma therapy. European Journal of Medicinal Chemistry, 2017, 139, 573-586.	2.6	31
13	The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. The National Catholic Bioethics Quarterly, 2017, 17, 661-671.	0.1	0
14	SLC2A8 (GLUT8) is a mammalian trehalose transporter required for trehalose-induced autophagy. Scientific Reports, 2016, 6, 38586.	1.6	87
15	Mo1528 GLUT8 (SLC2A8) Is a Mammalian Trehalose Transporter Required for Trehalose-Induced Autophagy. Gastroenterology, 2016, 150, S715.	0.6	0
16	Mammalian Glucose Transporter Activity Is Dependent upon Anionic and Conical Phospholipids. Journal of Biological Chemistry, 2016, 291, 17271-17282.	1.6	53
17	A Novel Fluorescence Resonance Energy Transfer-Based Screen in High-Throughput Format To Identify Inhibitors of Malarial and Human Glucose Transporters. Antimicrobial Agents and Chemotherapy, 2016, 60, 7407-7414.	1.4	16
18	Trehalose inhibits solute carrier 2A (SLC2A) proteins to induce autophagy and prevent hepatic steatosis. Science Signaling, 2016, 9, ra21.	1.6	223

#	ARTICLE	IF	CITATIONS
19	Commentary. <i>Clinical Chemistry</i> , 2015, 61, 1444-1444.	1.5	0
20	Expression, purification, and functional characterization of the insulin-responsive facilitative glucose transporter <sc>GLUT</sc>4. <i>Protein Science</i> , 2015, 24, 2008-2019.	3.1	19
21	In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy. <i>Journal of Biological Chemistry</i> , 2015, 290, 14441-14453.	1.6	52
22	The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6203-6209.	1.4	26
23	HIV and Endocrine Disorders. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, xvii-xviii.	1.2	3
24	Isoform-selective Inhibition of Facilitative Glucose Transporters. <i>Journal of Biological Chemistry</i> , 2014, 289, 16100-16113.	1.6	16
25	Saxagliptin improves glucose tolerance but not survival in a murine model of dilated cardiomyopathy. <i>Cardiovascular Endocrinology</i> , 2012, 1, 74-82.	0.8	11
26	GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle. <i>Cardiovascular Diabetology</i> , 2012, 11, 63.	2.7	64
27	Molecular mechanisms for insulin resistance in treated HIV-infection. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2011, 25, 459-468.	2.2	42
28	Exenatide Improves Glucose Homeostasis and Prolongs Survival in a Murine Model of Dilated Cardiomyopathy. <i>PLoS ONE</i> , 2011, 6, e17178.	1.1	54
29	HIV Protease Inhibitors Act as Competitive Inhibitors of the Cytoplasmic Glucose Binding Site of GLUTs with Differing Affinities for GLUT1 and GLUT4. <i>PLoS ONE</i> , 2011, 6, e25237.	1.1	72
30	GS-8374, a Novel HIV Protease Inhibitor, Does Not Alter Glucose Homeostasis in Cultured Adipocytes or in a Healthy-Rodent Model System. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1377-1382.	1.4	6
31	Acute Sulfonylurea Therapy at Disease Onset Can Cause Permanent Remission of KATP-Induced Diabetes. <i>Diabetes</i> , 2011, 60, 2515-2522.	0.3	33
32	Liver regeneration is impaired in lipodystrophic fatty liver dystrophy mice. <i>Hepatology</i> , 2010, 52, 2109-2117.	3.6	63
33	Effects of the HIV Protease Inhibitor Ritonavir on GLUT4 Knock-out Mice. <i>Journal of Biological Chemistry</i> , 2010, 285, 36395-36400.	1.6	53
34	Genetic Disruption of Myostatin Reduces the Development of Proatherogenic Dyslipidemia and Atherogenic Lesions In <i>Ldlr</i> Null Mice. <i>Diabetes</i> , 2009, 58, 1739-1748.	0.3	51
35	The Role of Protease Inhibitors in the Pathogenesis of HIV-Associated Lipodystrophy: Cellular Mechanisms and Clinical Implications. <i>Toxicologic Pathology</i> , 2009, 37, 65-77.	0.9	82
36	Acipimox, an Inhibitor of Lipolysis, Attenuates Atherogenesis in LDLR-Null Mice Treated With HIV Protease Inhibitor Ritonavir. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 2028-2032.	1.1	9

#	ARTICLE	IF	CITATIONS
37	HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy. <i>FASEB Journal</i> , 2008, 22, 2161-2167.	0.2	25
38	HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 660-665.	1.5	35
39	Tipranavir Without Ritonavir Does Not Acutely Induce Peripheral Insulin Resistance in a Rodent Model. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, 624-625.	0.9	12
40	Rosiglitazone inhibits mouse liver regeneration. <i>FASEB Journal</i> , 2006, 20, 2609-2611.	0.2	47
41	Molecular Mechanisms for Altered Glucose Homeostasis in HIV Infection. <i>American Journal of Infectious Diseases</i> , 2006, 2, 187-192.	0.1	28
42	Direct Comparison of the Acute In Vivo Effects of HIV Protease Inhibitors on Peripheral Glucose Disposal. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 398-403.	0.9	56
43	Delayed Hepatocellular Mitotic Progression and Impaired Liver Regeneration in Early Growth Response-1-deficient Mice. <i>Journal of Biological Chemistry</i> , 2004, 279, 43107-43116.	1.6	85
44	A Structural Basis for the Acute Effects of HIV Protease Inhibitors on GLUT4 Intrinsic Activity. <i>Journal of Biological Chemistry</i> , 2004, 279, 55147-55152.	1.6	73
45	Disruption of hepatic adipogenesis is associated with impaired liver regeneration in mice. <i>Hepatology</i> , 2004, 40, 1322-1332.	3.6	200
46	HIV Protease Inhibitors Acutely Impair Glucose-Stimulated Insulin Release. <i>Diabetes</i> , 2003, 52, 1695-1700.	0.3	114
47	Indinavir Induces Acute and Reversible Peripheral Insulin Resistance in Rats. <i>Diabetes</i> , 2002, 51, 937-942.	0.3	93
48	Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. <i>Aids</i> , 2002, 16, 859-863.	1.0	203
49	Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2001, 280, E549-E553.	1.8	47
50	Structural analysis of the GLUT1 facilitative glucose transporter. <i>Molecular Membrane Biology</i> , 2001, 18, 183-193.	2.0	142
51	The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy. <i>Journal of Biological Chemistry</i> , 2000, 275, 20251-20254.	1.6	507
52	Cysteine-Scanning Mutagenesis of Transmembrane Segment 11 of the GLUT1 Facilitative Glucose Transporter. <i>Biochemistry</i> , 2000, 39, 9367-9372.	1.2	37
53	Cysteine-scanning Mutagenesis of Transmembrane Segment 7 of the GLUT1 Glucose Transporter. <i>Journal of Biological Chemistry</i> , 1999, 274, 36176-36180.	1.6	48
54	3-Hydroxy-3-methylglutaryl coenzyme A lyase (HL): cloning and characterization of a mouse liver HL cDNA and subchromosomal mapping of the human and mouse HL genes. <i>Mammalian Genome</i> , 1993, 4, 382-387.	1.0	30

#	ARTICLE	IF	CITATIONS
55	3-Hydroxy-3-methylglutaryl dithio-CoA: utility of an alternative substrate in elucidation of a role for HMG-CoA lyase's cation activator. <i>BBA - Proteins and Proteomics</i> , 1993, 1162, 149-154.	2.1	9
56	Avian 3-hydroxy-3-methylglutaryl-CoA lyase: Sensitivity of enzyme activity to thiol/disulfide exchange and identification of proximal reactive cysteines. <i>Protein Science</i> , 1992, 1, 1144-1153.	3.1	26
57	3-Hydroxy-3-methylglutaryl coenzyme A lyase: affinity labeling of the <i>Pseudomonas mevalonii</i> enzyme and assignment of cysteine-237 to the active site. <i>Biochemistry</i> , 1992, 31, 6842-6847.	1.2	25